MC2 Therapeutics borrows money to make it to 2024: Lost more than USD 15m in 2022
It has apparently been extremely expensive for Danish biotech company MC2 Therapeutics to roll out the psoriasis drug Wynzora (betamethasone/calcipotriol) in the US.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.